Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer

We sought to characterise whether dexamethasone (DEX) may enhance tumour response to docetaxel in in vitro and in vivo models of metastatic prostate cancer (CaP). In vitro experiments conducted on PC3 and human bone marrow endothelial cells (hBMECs) determined that administration of DEX (10 nM) redu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wilson, C, Scullin, P, Worthington, J, Seaton, A, Maxwell, P, O'Rourke, D, Johnston, P G, McKeown, S R, Wilson, R H, O'Sullivan, J M, Waugh, D J J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2008
Soggetti:
Molecular Diagnostics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2607236/
https://ncbi.nlm.nih.gov/pubmed/19050703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604804
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi